Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure
Authors:
- S Di GiambenedettoSGS Di Giambenedetto
- A De LucaALA De Luca
- P VillaniPVP Villani
- A BacarelliABA Bacarelli
- E RagazzoniERE Ragazzoni
- M RegazziMRM Regazzi
- R CaudaRCR Cauda
- P NavarraPNP Navarra
- 23 March 2008
- journal article
- Published by Wiley in HIV Medicine
- Vol. 9 (4) , 239-245
Abstract
Objectives: Studies on the pharmacokinetic interaction between atazanavir and lopinavir with ritonavir (lopinavir/ritonavir) report contradictory results. We aimed to establish the in vivo interaction between these two protease inhibitors as well as the variables influencing drug exposure.Methods: Pharmacokinetic parameters were investigated in HIV‐infected patients treated with atazanavir 300 mg with ritonavir 100 mg q24h (group A) or lopinavir/ritonavir 400/100 mg q12h (group B) or atazanavir 300 mg q24h with lopinavir/ritonavir 400/100 mg q12h (group C). Patients receiving other concomitant protease inhibitors or non‐nucleoside reverse transcriptase inhibitors were excluded.Results: In group A (n=10), mean ± standard deviation atazanavir Cmin was 390 ± 460 ng/mL, Cmax 3051 ± 1996 ng/mL and AUC24 29 913 ± 17 686 ng/mL/h. In group B (n=9), lopinavir Cmin was 7562 ± 4292 ng/mL, Cmax 12 944 ± 4838 ng/mL and AUC0–12 122 313 ± 38 225 ng/mL/h. In group C (n=7), atazanavir Cmin was 876 ± 460 ng/mL (P=0.039 vs. group A), Cmax 3421 ± 3399 ng/mL and AUC0–24 65 055 ± 49 843 ng/mL/h (two‐sided P>0.05 for each comparison with group A), lopinavir Cmin was 7471 ± 3745 ng/mL, Cmax 10 143 ± 5217 ng/mL and AUC0–12 104 501 ± 43 565 ng/mL/h (P>0.05 for each comparison with group B). When analysing all the groups, including controls from routine clinical practice, higher body mass index was associated with lower atazanavir Cmin and with lower lopinavir Cmax. Atazanavir Cmin showed a correlation with total bilirubin levels.Conclusions: Combination with lopinavir/ritonavir provides higher atazanavir Cmin than combination with ritonavir alone, possibly because of an effect of the additional ritonavir dose. Low BMI may be associated with higher drug exposure.Keywords
This publication has 16 references indexed in Scilit:
- The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied researchAIDS, 2007
- Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimenAIDS, 2006
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresAIDS, 2006
- Clinical benefit of interventions driven by therapeutic drug monitoringHIV Medicine, 2005
- ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRODrug Metabolism and Disposition, 2005
- Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAIDS, 2005
- AtazanavirDrugs, 2005
- Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced PatientsHIV Research & Clinical Practice, 2004
- Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirAIDS, 2004
- In Vitro Antiviral Interaction of Lopinavir with Other Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2002